세계의 골반장기탈출증(POP : Pelvic Organ Prolapse) 치료 및 관리 시장 예측(-2030년) : 제품, 치료, 용도, 최종사용자, 지역별

The global POP Treatment and Management / Pelvic Organ Prolapse market is projected to reach USD 1.06 billion by 2030 from USD 0.77 billion in 2025, at a CAGR of 6.6% during the forecast period.

The market is expected to witness high growth due to the high global prevalence of pelvic organ prolapse, rising geriatric female population, growing awareness and early diagnosis, and advancements in minimally invasive and robotic surgical techniques. Complications and recalls associated with vaginal mesh, limited access and affordability in developing markets, underdiagnosis due to social stigma, and the risk of POP products are likely to restrain market growth.

"The hospitals segment of the POP Treatment and Management / Pelvic Organ Prolapse market, by end user, is expected to hold the largest position during the forecast period."

Based on end user, the market is segmented into hospitals, specialty clinics, ambulatory surgery centers (ASCs), and others. In 2024, hospitals and clinics accounted for the largest share of the market. Hospitals benefit from centralized procurement systems, allowing for efficient integration of new POP technologies. Their access to government or institutional funding also facilitates the acquisition of expensive devices, such as robotic surgical systems, which may not be feasible in smaller outpatient facilities. Furthermore, hospitals are often the only facilities equipped to manage intraoperative complications, complex reconstructions, and comorbid conditions in elderly patients-ensuring their continued dominance in the pelvic organ prolapse treatment landscape.

"The surgical segment accounted for the larger market share in the POP Treatment and Management / Pelvic Organ Prolapse market."

The POP Treatment and Management / Pelvic Organ Prolapse market is segmented into surgical and non-surgical. The surgical segment accounted for the larger share of the market in 2024. Surgical intervention is often preferred in cases involving multiple-compartment prolapses or associated conditions like stress urinary incontinence. Moreover, with the growing availability of minimally invasive and robotic-assisted methods, surgical options now offer quicker recovery and reduced postoperative complications, making them more acceptable to both patients and clinicians. Continuous innovation in surgical meshes, biologic grafts, and energy-assisted dissection tools further enhances procedural outcomes. Importantly, surgical treatments are backed by strong clinical guidelines and are often the first-line recommendation in moderate to severe POP, reinforcing their dominant position in the market.

"Asia Pacific is the fastest-growing market for POP Treatment and Management / Pelvic Organ Prolapse."

The global POP Treatment and Management / Pelvic Organ Prolapse market is segmented into five segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is experiencing rapid population aging, especially in countries like China and Japan, leading to a rising incidence of pelvic organ prolapse disorders among elderly women. Increasing awareness of women's health and growing acceptance of pelvic floor treatments are driving higher diagnosis and treatment rates. Governments across the region are investing in healthcare infrastructure, expanding access to surgical facilities, and supporting the adoption of advanced medical technologies, including robotic-assisted procedures. The rise of medical tourism in countries such as India and South Korea further fuels market growth, offering high-quality care at lower costs. While access disparities and a shortage of trained specialists still exist in rural areas, ongoing investments in healthcare training, digital health platforms, and public awareness campaigns are helping to close these gaps, positioning Asia Pacific as the fastest-growing regional market.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
• By Designation: C Level: 27%, Director Level: 18%, and Others: 55%
• By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4%

Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the POP Treatment and Management / Pelvic Organ Prolapse market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Intuitive Surgical Operations, Inc. (US), CooperCompanies (US), and Johnson & Johnson (US).

Research Coverage

This report studies the POP Treatment and Management / Pelvic Organ Prolapse market based on product, treatment, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, will help them to garner a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.

This report provides insights into the following pointers:

Analysis of key drivers (High global prevalence of pelvic organ prolapse, rising geriatric female population, growing awareness and early diagnosis, and advancements in minimally invasive and robotic surgical techniques), restraints (complications and recalls associated with vaginal mesh, limited access and affordability in developing market, and underdiagnosis due to social stigma), opportunities (growth opportunities in emerging economies, development of bioengineered and absorbable mesh and digital health and pelvic floor therapy devices), and challenges (inconsistent clinical guidelines and treatment standards, and high recurrence and reoperation rates)

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the POP Treatment and Management / Pelvic Organ Prolapse market

Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the POP Treatment and Management / Pelvic Organ Prolapse market

Market Development: Comprehensive information on lucrative emerging regions

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the POP Treatment and Management / Pelvic Organ Prolapse market

Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 List of secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 List of primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Breakdown of primary interviews
    • 2.1.2.4 Insights from industry experts
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Revenue estimation of key players
    • 2.2.1.2 Approach 2: Study of annual reports and investor presentations
    • 2.2.1.3 Approach 3: Primary interviews
    • 2.2.1.4 Growth forecast
    • 2.2.1.5 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
  • 2.4.1 STUDY-RELATED ASSUMPTIONS
  • 2.4.2 PARAMETRIC ASSUMPTIONS
  • 2.4.3 GROWTH RATE ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PELVIC ORGAN PROLAPSE/ PELVIC FLOOR RECONSTRUCTION MARKET
• 4.2 ASIA PACIFIC PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER AND COUNTRY
• 4.3 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY REGION
• 4.4 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Global prevalence of pelvic organ prolapse
    • 5.2.1.2 Rise in female geriatric population
    • 5.2.1.3 Improved awareness and early diagnosis
    • 5.2.1.4 Advancements in robotic surgical techniques
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Complications and recalls associated with transvaginal synthetic mesh
    • 5.2.2.2 Limited access in emerging economies
    • 5.2.2.3 Underdiagnosis due to social stigma
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increased investments in pelvic organ prolapse care from emerging economies
    • 5.2.3.2 Rapid development of bioengineered and absorbable mesh
    • 5.2.3.3 Advent of digital pelvic health solutions
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Inconsistent clinical guidelines and treatment standards
    • 5.2.4.2 High recurrence and reoperation rates
• 5.3 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY TREATMENT AND KEY PLAYER
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Pelvic mesh implants
    • 5.9.1.2 Vaginal pessaries
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Wearable and app-based pelvic therapy devices
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Urinary incontinence devices
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT SCENARIO (HS CODE 901890)
  • 5.11.2 EXPORT SCENARIO (HS CODE 901890)
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 NEGLECTED PESSARY IN PATIENT WITH PELVIC ORGAN PROLAPSE
  • 5.13.2 SUCCESSFUL USE OF PESSARY FOR UTERINE PROLAPSE AFTER PELVIC TRAUMA IN YOUNG, NULLIPAROUS FEMALE
  • 5.13.3 ROBOTIC AND LAPAROSCOPIC SACROCOLPOPEXY FOR PELVIC ORGAN PROLAPSE
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY ANALYSIS
    • 5.14.1.1 North America
      • 5.14.1.1.1 US
      • 5.14.1.1.2 Canada
    • 5.14.1.2 Europe
      • 5.14.1.2.1 Germany
      • 5.14.1.2.2 UK
      • 5.14.1.2.3 France
    • 5.14.1.3 Asia Pacific
      • 5.14.1.3.1 China
      • 5.14.1.3.2 Japan
      • 5.14.1.3.3 India
    • 5.14.1.4 Latin America
    • 5.14.1.5 Middle East
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 BARGAINING POWER OF SUPPLIERS
  • 5.15.2 BARGAINING POWER OF BUYERS
  • 5.15.3 THREAT FROM NEW ENTRANTS
  • 5.15.4 THREAT FROM SUBSTITUTES
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 IMPACT OF AI
  • 5.17.1 INTRODUCTION
  • 5.17.2 POTENTIAL OF AI IN PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET
  • 5.17.3 KEY COMPANIES IMPLEMENTING AI
  • 5.17.4 FUTURE OF AI IN PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET
• 5.18 US 2025 TARIFF
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals

6 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 SYNTHETIC MESH
  • 6.2.1 ADOPTION OF ADVANCED, PATIENT-FOCUSED MESH TECHNOLOGIES
• 6.3 BIOLOGICAL GRAFTS
  • 6.3.1 SHIFT TOWARD BIOCOMPATIBLE ALTERNATIVES
• 6.4 SUTURES
  • 6.4.1 NEED FOR PRECISION IN PELVIC REPAIRS WITH ABSORBABLE AND ANTIBACTERIAL PRODUCTS
• 6.5 VAGINAL PESSARIES
  • 6.5.1 INTRODUCTION OF CUSTOM-FIT, HOME-USE PESSARY SOLUTIONS
• 6.6 PELVIC FLOOR THERAPY DEVICES
  • 6.6.1 PATIENT PREFERENCE FOR MANAGING PELVIC FLOOR DISORDERS INDEPENDENTLY
• 6.7 ROBOTIC SURGERY SYSTEMS
  • 6.7.1 ELEVATED DEMAND FOR MINIMALLY INVASIVE SOLUTIONS IN COMPLEX PELVIC REPAIRS
• 6.8 DIAGNOSTIC & ASSESSMENT TOOLS
  • 6.8.1 ACCURATE DETECTION WITH ADVANCED IMAGING AND SMART DEVICES

7 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT

• 7.1 INTRODUCTION
• 7.2 SURGICAL
  • 7.2.1 COLPOCLEISIS
    • 7.2.1.1 Large-scale adoption among older women
  • 7.2.2 COLPORRHAPY
    • 7.2.2.1 Increased preference for foundational repair techniques
  • 7.2.3 SACROCOLPOPEXY
    • 7.2.3.1 Reduced postoperative discomfort and quicker recovery
  • 7.2.4 SACROHYSTEROPEXY
    • 7.2.4.1 Rise in demand for uterine-preserving options for prolapse repair
  • 7.2.5 UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION
    • 7.2.5.1 Surge in native tissue repairs without mesh-based interventions
• 7.3 NON-SURGICAL
  • 7.3.1 VAGINAL PESSARY MANAGEMENT
    • 7.3.1.1 Emphasis on early intervention
  • 7.3.2 PELVIC FLOOR MUSCLE THERAPY
    • 7.3.2.1 Extensive use in early-stage prolapse and postpartum women

8 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 CYSTOCELE
  • 8.2.1 WEAKENED PELVIC FLOOR MUSCLES PROMPT DEVELOPMENT
• 8.3 URETHROCELE
  • 8.3.1 CHRONIC INCREASE IN INTRA-ABDOMINAL PRESSURE
• 8.4 ENTEROCELE
  • 8.4.1 SURGE IN APICAL VAGINAL SUPPORT DEFICIENCY
• 8.5 UTERINE PROLAPSE
  • 8.5.1 GROWTH IN PROLAPSE BURDEN
• 8.6 RECTOCELE
  • 8.6.1 PREVALENCE OF RECTOVAGINAL SEPTUM DEFICIENCY

9 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS
  • 9.2.1 HIGH PATIENT INFLOW AND WIDESPREAD AVAILABILITY OF REIMBURSEMENTS
• 9.3 SPECIALTY CLINICS
  • 9.3.1 HEIGHTENED DEMAND FOR TAILORED, NON-INVASIVE, AND ACCESSIBLE CARE
• 9.4 AMBULATORY SURGERY CENTERS
  • 9.4.1 COST ADVANTAGES AND FAVORABLE CLINICAL OUTCOMES
• 9.5 OTHER END USERS

10 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK
  • 10.2.2 US
    • 10.2.2.1 Rise in female geriatric population to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 High symptom prevalence and demographic trends to drive market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK
  • 10.3.2 GERMANY
    • 10.3.2.1 Advanced surgical innovations to drive market
  • 10.3.3 FRANCE
    • 10.3.3.1 Increased clinical focus on pelvic floor disorders and pelvic organ prolapse to drive market
  • 10.3.4 UK
    • 10.3.4.1 Women's health policy initiatives to drive market
  • 10.3.5 ITALY
    • 10.3.5.1 Demographic shifts to drive market
  • 10.3.6 SPAIN
    • 10.3.6.1 Rising popularity of non-surgical interventions to drive market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK
  • 10.4.2 CHINA
    • 10.4.2.1 Growing incidence of pelvic organ prolapse to drive market
  • 10.4.3 JAPAN
    • 10.4.3.1 Evolving healthcare delivery and infrastructure landscape to drive market
  • 10.4.4 INDIA
    • 10.4.4.1 Booming medical tourism to drive market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Rapid growth of medical manufacturing companies to drive market
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Surge in healthcare spending to drive market
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK
  • 10.5.2 BRAZIL
    • 10.5.2.1 Improving healthcare infrastructure to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Expanding healthcare awareness and services to drive market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025
• 11.3 REVENUE ANALYSIS, 2022-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Product footprint
    • 11.5.5.4 Treatment footprint
    • 11.5.5.5 Application footprint
• 11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING
    • 11.6.5.1 List of start-ups/SMEs
    • 11.6.5.2 Competitive benchmarking of start-ups/SMEs
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES/APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 BOSTON SCIENTIFIC CORPORATION
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 COLOPLAST GROUP
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 MnM view
      • 12.1.2.3.1 Right to win
      • 12.1.2.3.2 Strategic choices
      • 12.1.2.3.3 Weaknesses and competitive threats
  • 12.1.3 INTUITIVE SURGICAL OPERATIONS, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches/approvals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 COOPERCOMPANIES
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 JOHNSON & JOHNSON
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches/approvals
      • 12.1.5.3.2 Deals
      • 12.1.5.3.3 Other developments
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 GE HEALTHCARE
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches/approvals
      • 12.1.6.3.2 Deals
      • 12.1.6.3.3 Other developments
  • 12.1.7 INTEGRA LIFESCIENCES CORPORATION
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
  • 12.1.8 B. BRAUN SE
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
  • 12.1.9 PFM MEDICAL GMBH
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 CALDERA MEDICAL
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 KEGEL8
  • 12.2.2 MEDGYN PRODUCTS INC.
  • 12.2.3 BETATECH MEDICAL
  • 12.2.4 FEG TEXTILTECHNIK FORSCHUNGS- UND ENTWICKLUNGSGESELLSCHAFT MBH
  • 12.2.5 BIOTEQUE AMERICA INC.
  • 12.2.6 PERSONAL MEDICAL CORP.
  • 12.2.7 DIPROMED SRL
  • 12.2.8 A.M.I. GMBH
  • 12.2.9 BRAY GROUP
  • 12.2.10 DIGITIMER LTD
  • 12.2.11 MEDESIGN I.C. GMBH
  • 12.2.12 DR. ARABIN GMBH & CO. KG
  • 12.2.13 FOR.ME.SA.
  • 12.2.14 COSM MEDICAL
  • 12.2.15 WILLOW INNOVATIONS, INC.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS